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Within a decade of its invention, the technology
commonly termed ‘‘DNA ﬁngerprinting’’ trans-
formed forensic science and had a huge impact on the
legal system. Thanks to this procedure, which com-
bines polymerase chain reaction for sequence ampli-
ﬁcation and capillary electrophoresis as a sensitive
high-throughput detection method, it is now practical
to evaluate small amounts of degenerated DNA and
interrogate multiple known sites of highly variable
genetic sequence, known as microsatellites. In foren-
sic sciences, a perfect match of sequence at multiple
microsatellites is used to assign identity with near
certainty. This technology is applicable to the de-
graded DNA of formalin-ﬁxed tissues and has been
successfully applied to breast cancers by Ellsworth
et al.1 In the article by Becker et al.,2 this same re-
search group has interrogated 26 microsatellite loci
scattered across the genome and has applied statisti-
cal models to estimate the similarity between the
primary tumor and each nodal metastasis in 26 pa-
tients with node-positive breast cancer. This work
builds on previous studies that have applied tech-
niques such as DNA ploidy, immunohistochemical
markers, ﬂuorescent in situ hybridization, compara-
tive genomic hybridization, and gene expression
proﬁling to explore the clonal progression model of
cancer due to its characteristic genomic instability.
The investigators attempted to map the order of
each metastasis. Assuming that allelic imbalances
(AIs) of microsatellite genetic sequence continue to
accrue during tumor progression (but do not disap-
pear), they supposed that the most recent nodal
metastases would have the most AIs and the highest
similarity to the primary tumor sample, whereas
older metastases would have fewer AIs. This is the
basis of the heritage maps that they present as pos-
sible timelines of nodal metastases in each patient. Of
course, there is no way of proving the timing of each
metastasis in a patient at the time of surgery, but the
concept is intriguing.
A number of unaccounted factors could also aﬀect
this model. First, primary breast cancers are often
biologically heterogeneous, such that the single
sample of each primary tumor evaluated in this study
might not fully represent that heterogeneity. The
frequent observation in some nodal metastases of AI
at genetic sites that were normal in the primary tumor
sample could be explained by intratumoral hetero-
geneity that was not appreciated from one sample.
Second, it is likely that metastases also exhibit genetic
instability during their growth. This could produce
new genetic sites of AI in some metastases, but not in
the primary tumor. Third, because the lymphatic
drainage routes persist, it is likely that nodal metas-
tases continue to be seeded by the primary tumor
(and even upstream nodal metastases) such that new
clones are periodically added to an existing metastatic
population. Combinations of these possible factors
would add to the chaos.
In future studies, it would be interesting to apply
this technology to current specimens from sentinel
lymph nodes, from which certain inferences could be
made about what constitutes a recent nodal metas-
tasis, or about possible patterns of involvement. One
could also explore whether metastases have greater
genetic instability with more advanced nodal stage,
possibly adding to the prognostic relevance.
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Questions that arise from this article also relate to
clinical management. To what extent is genomic
instability a reﬂection of tumor phenotype, and to
what extent is the rate of genomic instability a factor in
prognosis and treatment resistance? The ﬁrst question
cannot be addressed by using only 26 selected cases,
but it is potentially answerable. The authors suggest
that genomic instability may relate to treatment fail-
ure, but proof is not forthcoming. Indeed, we can
ponder that the incurability of stage IV disease could
be attributable to accelerated genetic chaos in addition
to the rate of growth and overall burden of disease.
This technology can be applied to archival tissue
samples, and probably also cytologic samples with
alcohol-based ﬁxation, and so could be used to deter-
mine the extent and rate of genomic instability during
the course of disease progression in patients who have
undergone biopsy at times of relapse. Temporal het-
erogeneity is certain to be a relevant biological factor
that canonly be evaluated in serial samples. Indeed, the
biology of distant metastasis is a high priority for
translational breast cancer research.
When one considers that 26 microsatellites repre-
sent a few tiny specks on the canvas of the cancer
genome, it becomes apparent that we know little of a
complex and evolving picture. However, studies such
as this will shape new hypotheses and help to direct
future research.
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